Lilly Diabetes Drug Meets Endpoints in Phase 3 Trials

 Eli Lilly & Co. said Wednesday that its tirzepatide drug for type 2 diabetes met the endpoints of two Phase 3 clinical trials.

The once-weekly drug, a dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist, significantly reduced A1C and body weight in patients who used it in the trial, the company said.

Pre-clinical models had showed that GIP helps reduce food intake and increase energy use by the body, leading to weight loss. The combination with a GLP-1 receptor can increase the effect, Lilly said.

In both of the two Phase 3 trials, more than 90% of patients who were given the drug achieved A1C of less than 7%, the American Diabetes Association's recommended target for people with diabetes. Patients who used the drug in the trials typically lost 5 to 11 kilograms during the observation period, or roughly 11 to 24 pounds.

The most common adverse events in the trials were mild to moderate gastrointestinal issues, the company said.

Lilly said the results will be published in a peer-reviewed publication this year.

https://www.marketscreener.com/quote/stock/ELI-LILLY-AND-COMPANY-13401/news/Eli-Lilly-and-Diabetes-Drug-Meets-Endpoints-in-Phase-3-Trials-32461620/